#United States #Centinel Spine #prodisc #West Chester, PA #TDR technology

Centinel Spine Celebrates 35 Years of prodisc® Innovation

Centinel Spine®, a prominent global medical device company, recently celebrated an impressive 35 years of clinical excellence with its prodisc® platform. This milestone is not just a testament to the longevity of the technology, but also highlights its continuous evolution and innovation in the field of total disc replacement (TDR).

Since the first successful implantation of the prodisc® in 1990, the platform has witnessed significant advancements, backed by over 540 published studies. These peer-reviewed papers evidence the technology's efficacy, indicating a remarkable revision rate of less than 1%, showcasing its reliability in restoring spinal function.

Dr. Thierry Marnay, the orthopedic spine surgeon who pioneered the prodisc technology, initiated the journey in Montpellier, France. His vision was driven by a critical orthopedic challenge: finding a reliable method to maintain natural spinal motion in patients suffering from degenerative disc disease. Over the years, with more than 300,000 successful implantations performed, prodisc has not only preserved motion but significantly improved patients' quality of life.

In the last five years, Centinel Spine has propelled the prodisc platform into a new era of innovation. The introduction of expanded cervical and lumbar patient indications, along with new anatomic implant offerings, stands testament to the company’s commitment to fostering cutting-edge advancements tailored to the needs of modern surgical practice. Prodisc is now uniquely positioned as the only TDR solution authorized by the FDA for both one-and two-level indications in cervical and lumbar applications.

Among the noteworthy milestones achieved since 2020 are the following:

• - The FDA’s approval of two-level indications for the prodisc L lumbar TDR device.
• - The launch of Anatomic Endplate™ options within the prodisc L system, enhancing surgeon versatility.
• - The introduction of the prodisc C Vivo and prodisc C SK Match-the-Disc™ cervical TDR systems, presenting anatomically-differentiated implant options.
• - The limited commercial release of the prodisc C Nova device, thus providing four unique FDA-approved options for cervical TDR.
• - New instrumentation designed for the prodisc L system, streamlining surgical procedures and enhancing user-friendliness.
• - Recent FDA approvals for two-level usage in prodisc C Vivo and prodisc C SK devices, cementing their status as the only cervical TDR solutions available in multiple configurations.

Centinel Spine has also reaffirmed its commitment to medical education and support for both surgeons and patients. Enhanced educational initiatives, bolstered patient access programs, and dedicated surgeon resources are now part of their comprehensive strategy to navigate the evolving landscape of total disc replacement.

Dr. Scott Blumenthal, an orthopaedic surgeon and trailblazer in the realm of TDR, shared insights reflecting on his extensive career dedicated to this surgical intervention. As the first surgeon to carry out a total disc replacement in the U.S. over 25 years ago, Dr. Blumenthal has conducted over 5,000 TDR surgeries. His experience affirms that the utility of total disc replacement technology is far broader than commonly understood, promising exciting advancements in the years ahead.

Summarizing the company’s vision, Centinel Spine CEO Steve Murray expressed, “As we enter this next era of total disc replacement, our mission remains unchanged: to deliver innovation driven by evidence that significantly enhances patient care.” His assertion reinforces the company’s confidence in the continuing evolution of the prodisc platform, pledging to maintain its status at the forefront of the TDR field.

As Centinel Spine celebrates this 35-year legacy of prodisc, it not only honors its past but also looks forward to shaping the future of spinal health through transformative innovation.